EUVIMEDEUVIMED entdecken
Crossref

Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data

R Boscke, M Heidemann, K-L Bruchhage

Rhinology Journal · 01.03.2023 · 0-0

DOI: 10.4193/rhin22.469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rhinology Journal, online erschienen am 01.03.2023. Verfasst von R Boscke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Carl-von-Ossietzky University of Oldenburg, Oldenburg, Germany; Department of Otorhinolaryn…. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinitis, Sinusitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab, an IL-4/13 receptor inhibitor, is approved for the treatment of uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Methodology: We evaluated the effectiveness and safety of dupilumab for CRSwNP based on retrospective 12-month follow-up data of 41 patients. We analysed nasal endoscopy scores, patient-reported outcome measures (PROMs), 12-item Sniffin’-Sticks odor identification test (SSIT-12), total serum IgE, serum Eosinophilic Cationic Protein (ECP), and total blood eosinophil count (BEC). We performed statistical analysis using non-parametric ANOVA-type models and Spearman’s correlation.

Results

At month 1, endoscopy scores, PROMs and SSIT-12 showed meaningful improvements that were maintained until month 12. Initial elevations in both median ECP and BECs returned to near baseline levels by month 12. The percentage of patients withBEC ≥0.6 remained increased at month 12 (42.1%) compared to baseline (19.5%). Total serum IgE levels decreased progressively and correlated with nasal polyp scores at month 12. “Adequate response” was reached in 86.8% of our cohort.

Conclusions

Our data suggest that dupilumab is effective for the treatment of CRSwNP. The potential for short- and long-term BEC elevations in some CRSwNP patients should be carefully monitored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsRhinitisSinusitisHumansRetrospective StudiesChronic DiseaseImmunoglobulin EAntibodies, Monoclonal, Humanized

Substanzen

Immunoglobulin EdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, Carl-von-Ossietzky University of Oldenburg, Oldenburg, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, University of Lubeck, Lubeck, Germany.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University of Lubeck, Lubeck, Germany.

Zitieren

APA

Boscke, R., Heidemann, M., & Bruchhage, K. L. (2023). Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin22.469

Vancouver

Boscke R, Heidemann M, Bruchhage KL. Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data. Rhinology Journal. 2023;0(0):0-0. doi:10.4193/rhin22.469

BibTeX
@article{Boscke2023,
  author = {Boscke, R and Heidemann, M and Bruchhage, K-L},
  title = {Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data},
  journal = {Rhinology Journal},
  year = {2023},
  volume = {0},
  number = {0},
  pages = {0--0},
  doi = {10.4193/rhin22.469}
}
Kostenlos starten →